scholarly journals P2.01-102 Comprehensive Next-Generation Sequencing Guided Targeted Therapies Improve Clinical Outcomes of Lung Cancer Patients

2018 ◽  
Vol 13 (10) ◽  
pp. S704 ◽  
Author(s):  
Z. Wang ◽  
D. Zhu ◽  
B. Lu ◽  
G. Liu ◽  
T. Xu
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Targeted Therapies ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Generation Sequencing

Targeted gene sequencing panel for identifying actionable genomic alterations in Taiwanese lung cancer patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20522-e20522
Author(s):  
Yen-Jung Lu ◽  
Kien Thiam Tan ◽  
Chun-Jung Chen ◽  
Ren-Shiang Jhou ◽  
Yi-Ting Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Targeted Therapies ◽  
Copy Number ◽  
Egfr Mutations ◽  
Next Generation ◽  
Genomic Alterations ◽  
Lung Cancer Patients ◽  
Generation Sequencing

e20522 Background: Lung cancer boasts an arsenal of targeted therapies directed at various molecular aberrations such as EGFR mutations and fusion genes. Simultaneous assessment for genetic alterations provides biomarkers to assist clinicians in their treatment selections. Methods: A total of 43 FFPE (formalin-fixed, paraffin-embedded) samples obtained from lung cancer patients in Taiwan were subjected to next-generation sequencing (NGS), using a compact panel encompassing 17 potentially actionable, lung cancer-associated genes. NGS was performed on the Ion Torrent PGM or Proton System with a targeted average depth of > 800x. Genomic alterations detected were categorized as single nucleotide variants (SNV) or chromosomal copy number alterations (CNA). Results: A total of 74 putatively actionable genomic alterations were detected across 38 patients (88.4%), which may predict sensitivity or resistance to established and/or therapies that are still in clinical development. 19 patients (44.2%) had tumors harboring activating EGFR mutations in the tyrosine kinase (TK) domain – L858R substitution or exon 19 deletion, which may suggest clinical benefit to first- and second-generation EGFR TK inhibitors (TKIs). Three patients (7.0%) whose tumor had acquired the EGFR T790M mutation were advised to switch to third-generation EGFR TKI. Possible resistance mechanisms to EGFR TKIs via increased copy number of EGFR (14.0%, n = 6) and MET (11.6%, n = 5) were observed. Deletion or loss of CDKN2A gene were detected in 14 patients (32.6%), which may confer sensitivity to CDK4/6 inhibitors. Inhibition of downstream effectors in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways were suggested for patients whose tumor harbored PIK3CA and/or KRAS oncogenic mutations. Conclusions: Next-generation sequencing using a compact panel of genes may be sufficient to identify biomarkers for targeted therapies selection for most lung cancer patients in Taiwan.

Spectrum of Pathogenic Germline Mutations in Chinese Lung Cancer Patients through Next-Generation Sequencing

2019 ◽  
Vol 26 (1) ◽  
pp. 109-114 ◽  
Author(s):  
Panwen Tian ◽  
Xiangyang Cheng ◽  
Zhengyi Zhao ◽  
Yuzi Zhang ◽  
Celimuge Bao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Germline Mutations ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Generation Sequencing

Next-generation sequencing in metastatic lung cancer patients: Translation from sequence data into clinical practice.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12521-e12521
Author(s):  
Jessica Ribeiro Gomes ◽  
Raphael Brandao Moreira ◽  
Renata D'Alpino D'Alpino ◽  
Marcelo Rocha S Cruz ◽  
Tercia Tarciane Soares de Sousa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Practice ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Sequence Data ◽  
Metastatic Lung Cancer ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Metastatic Lung ◽  
Generation Sequencing

scholarly journals Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Julie A. Vendrell ◽  
Sylvie Taviaux ◽  
Benoît Béganton ◽  
Sylvain Godreuil ◽  
Patricia Audran ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Fusion Transcripts ◽  
Generation Sequencing

scholarly journals Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing

2020 ◽  
Vol 52 (2) ◽  
pp. 543-551 ◽  
Author(s):  
Eunhyang Park ◽  
Hyo Sup Shim
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Single Gene ◽  
Advanced Stage ◽  
Next Generation ◽  
Lung Cancer Patients ◽  
Advanced Stage Lung Cancer ◽  
Generation Sequencing ◽  
Stage Lung Cancer

PurposeEpidermal growth factor receptor (<i>EGFR</i>), anaplastic lymphoma kinase (<i>ALK</i>), and ROS proto-oncogene 1 (<i>ROS1</i>) are ‘must-test’ biomarkers in the molecular diagnostics of advanced-stage lung cancer patients. Although single-gene assays are currently considered the gold standard for these genes, next-generation sequencing (NGS) tests are being introduced to clinical practices. We compared the results of current diagnostics and aimed to suggest timely effective guidance for their clinical use. Materials and MethodsPatients with lung cancer who received both conventional single-gene assays and subsequent targeted NGS testing were enrolled, and the results of their tests were compared. ResultsA total of 241 patients were enrolled, and the <i>EGFR</i> real-time polymerase chain reaction, <i>ALK</i> fluorescence <i>in situ</i> hybridization (FISH), and <i>ROS1</i> FISH assays exhibited 92.9%, 99.6%, and 99.5% concordance with the NGS tests, respectively. The discordant cases were mostly false-negatives of the single-gene assays, probably due to technical limitation. Of 158 cases previously designated as wild-type, <i>EGFR</i>, <i>ALK</i>, and <i>ROS1</i> alterations were identified in 10.1%, 1.9%, and 1.3%, respectively, and other targetable alterations were identified in 36.1% of the cases. Of patients with additionally identified actionable alterations, 32.6% (31/95) received matched therapy with a clinical benefit of 48.4% (15/31). ConclusionEven though the conventional and NGS methods were concordant in the majority of cases, NGS testing still revealed a considerable number of additional <i>EGFR</i>, <i>ALK</i>, and <i>ROS1</i> alterations, as well as other targetable alterations, in Korean advanced-stage lung cancer patients. Given the high frequency of <i>EGFR</i> and other targetable mutations identified in the present study, NGS testing is highly recommended in the diagnosis of Korean lung cancer patients.

Sign in / Sign up

Export Citation Format

Share Document